Thrombin-activated receptors: Promising targets for cancer therapy?

Current Medicinal Chemistry

Volumn 17, Issue 2, 2010, Pages 109-128

  Garcia Lopez M T ^a   Gutierrez Rodriguez M ^a   Herranz, R ^a  

^a INSTITUTO DE QUÍMICA MÉDICA   (Spain)

Author keywords

Angiogenesis; Cancer; PAR 1; PAR 1 agonists and antagonists; Protease activated receptors; Thrombin activated receptors

Indexed keywords

3A,4,4A,5,6,7,8,8A,9,9A DECAHYDRO N [4 [2 [5 (3 FLUOROPHENYL) 2 PYRIDYL]VINYL] 3 METHYL 1 OXO 3H BENZO[F]ISOBENZOFURAN 7 YL]CARBAMIC ACID ETHYL ESTER; BMS 200261; E 5555; FR 171113; HIMBACINE; HIRUDIN; LOW MOLECULAR WEIGHT HEPARIN; PEPTIDOMIMETIC AGENT; PROTEINASE ACTIVATED RECEPTOR 1; PROTEINASE ACTIVATED RECEPTOR 1 ANTAGONIST; PROTEINASE ACTIVATED RECEPTOR 2; PROTEINASE ACTIVATED RECEPTOR 3; PROTEINASE ACTIVATED RECEPTOR 4; RWJ 56110; RWJ 58259; SCH 203099; SCH 79797; THROMBIN; UNCLASSIFIED DRUG;

ANGIOGENESIS; BLOOD CLOTTING; CANCER INVASION; CANCER PATIENT; CANCER THERAPY; CARCINOGENESIS; CELL PROLIFERATION; CORRELATION ANALYSIS; DESENSITIZATION; DRUG ACTIVITY; DRUG BIOAVAILABILITY; DRUG STRUCTURE; DRUG TARGETING; HIGH THROUGHPUT SCREENING; HUMAN; METASTASIS; NONHUMAN; PHARMACOPHORE; PROTEIN EXPRESSION; PROTEIN INTERACTION; PROTEIN STRUCTURE; PROTEIN TARGETING; REVIEW; SIGNAL TRANSDUCTION; STRUCTURE ACTIVITY RELATION; THROMBOCYTE AGGREGATION; THROMBOSIS; TUMOR CELL; VENOUS THROMBOEMBOLISM;

ANIMALS; ANTINEOPLASTIC AGENTS; HUMANS; NEOPLASMS; PLATELET AGGREGATION INHIBITORS; RECEPTOR, PAR-1; THROMBIN;

EID: 77149124621     PISSN: 09298673     EISSN: None     Source Type: Journal    
DOI: 10.2174/092986710790112639     Document Type: Review

References (209)

1. Macfarlane, S. R.; Seatter, M. J.; Kanke, T.; Hunter, G. D.; Plevin, R. Proteinase-activated receptors. Pharmacol. Rev. 2001, 53, 245-282.
2. Martorell, L.; Martínez-Gonzàlez, J.; Rodríguez, C.; Gentile, M.; Calvayrac, O.; Badimon, L. Thrombin and protease-activated receptors (PARs) in atherothrombosis. Thromb. Haemost. 2008, 99, 305-315.
3. Ossovskaya, V. S.; Bunnett, N. W. Protease-activated receptors: contribution to physiology and disease. Physiol. Rev. 2004, 84, 579-621.
4. Sokolova, E.; Reiser, G. Prothrombin/thrombin and the thrombin receptors PAR-1 and PAR-4 in the brain: Localization, expression and participation in neurodegenerative diseases. Thromb. Haemost. 2008, 100, 576-581.
5. Luo, W.; Wang, Y.; Reiser, G. The role of thrombin and thrombin receptor in the brain. In Thrombin: Physiology and Disease, Maragoudakis, M. E.; Tsopanoglou, N. E., Eds. Springer: New York, 2009, pp. 133-159.
6. Steinhoff, M.; Buddenkotte, J.; Shpacovitch, V.; Rattenholl, A.: Moormann, C.; Vergnolle, N.; Luger, T. A.; Hollenberg, M. D. Proteinase-activated receptors: transducers of proteinase-mediated signaling in inflammation and immune response. Endocr. Rev. 2005, 26, 1-43.
7. Pagel, C. N.; Song, S.-J.; Loh, L. H.; Tudor, E. M.; Murray-Rust, T. A.; Pike, R. N.; Mackie, E. J. Thrombin-stimulated growth factor and cytokine expression in osteoblasts is mediated by proteaseactivated receptor-1 and prostanoids. Bone 2009, 44, 813-821.
8. Arora, P.; Ricks, T.K.; Trejo, J. Protease-activated receptor signalling, endocytic sorting and dysregulation in cancer. J. Cell Sci. 2007, 120, 921-928.
9. Camerer, E. Protease signaling in tumor progression. Thromb. Res. 2007, 120, S75-81.
10. Borensztajn, K. S.; Spek, C. A. Protease-activated receptors, apoptosis and tumor growth. Pathophysiol. Haemost. Thromb. 2008, 36, 137-147.
11. Kobrinsky, B.; Karpatkin, S. The role of thrombin in tumor biology. In Thrombin: Physiology and Disease, Maragoudakis, M. E.; Tsopanoglou, N. E., Eds. Springer: New York, 2009, pp. 161-172.
12. Coughlin, S. R. Thrombin signalling and protease-activated receptors. Nature, 2000, 407, 258-264.
13. th Ed., Watling, K. J. Ed. Proteinase-activated receptors. Sigma-Aldrich Research Biotechnology: Natick, 2006, pp. 210-211.
14. Nierodzik, M. L.; Karpatkin, S. Thrombin induces tumor growth, metastasis, and angiogenesis: Evidence for a thrombin-regulated dormant tumor phenotype. Cancer Cell 2006, 10, 355-362.
15. Boire, A.; Covic, L.; Agarwal, A.; Jacques, S.; Sherifi, S.; Kuliopulos, A. PAR1 is a matrix metalloprotease-1 receptor that promotes invasion and tumorigenesis of breast cancer cells. Cell. 2005, 120, 303-313.
16. Yin, Y.J.; Katz, V.; Salah, Z.; Maoz, M.; Cohen, I.; Uziely, B.; Turm, H.; Grisaru-Granovsky, S.; Suzuki, H.; Bar-Shavit, R. Mammary gland tissue targeted overexpression of human proteaseactivated receptor 1 reveals a novel link to beta-catenin stabilization. Cancer Res. 2006, 66, 5224-5233.
17. Tsopanoglou, N. E.; Pipili-Synetos, E.; Maragoudakis, M.E. Thrombin promotes angiogenesis by a mechanism independent of fibrin formation. Am. J. Physiol. 1993, 264, C1302-7.
18. Tsopanoglou, N. E.; Maragoudakis, M.E. The role of thrombin in angiogenesis. In Thrombin: Physiology and Disease, Maragoudakis, M. E.; Tsopanoglou, N. E., Eds. Springer: New York, 2009, pp. 93-113.
19. Zania, P.; Kritikou, S.; Flordellis, C. S.; Maragoudakis, M. E.; Tsopanoglou, N. E. Blockage of angiogenesis by small molecule antagonists to protease-activated receptor-1: association with endothelial cell growth suppression and induction of apoptosis. J. Pharmacol. Exp. Ther. 2006, 318, 246-254.
20. Tsopanoglou, N, E.; Maragoudakis, M. E. Inhibition of Angiogenesis by Small-Molecule Antagonists of Protease-Activated Receptor-1. Semin. Thromb. Hemost. 2007, 33, 680-687.
21. Vu, T. K.; Hung, D. T.; Wheaton, V. I.; Coughlin, S. R. Molecular cloning of a functional thrombin receptor reveals a novel proteolytic mechanism of receptor activation. Cell 1991, 64, 1057-1068.
22. Rasmussen, U. B.; Vouret-Craviari, V.; Jallat, S.; Schlesinger, Y.; Pagès, G.; Pavirani, A.; Lecocq, J. P.; Pouysségur, J.; Van Obberghen-Schilling, E. cDNA cloning and expression of a hamster alpha-thrombin receptor coupled to Ca2+ mobilization. FEBS Lett. 1991, 288, 123-128.
23. Blackhart, B. D.; Ruslim-Litrus, L.; Lu, C. C.; Alves, V. L.; Teng, W.; Scarborough, R. M.; Reynolds, E. E.; Oksenberg, D. Extracellular mutations of protease-activated receptor-1 result in differential activation by thrombin and thrombin receptor agonist peptide. Mol. Pharmacol. 2000, 58, 1178-1187.
24. Seeley, S.; Covic, L.; Jacques, S. L.; Sudmeier, J.; Baleja, J. D.; Kuliopulos, A. Structural basis for thrombin activation of a protease-activated receptor: inhibition of intramolecular liganding. Chem. Biol. 2003, 10, 1033-1041.
25. Nystedt, S.; Emilsson, K.; Wahlestedt, C.; Sundelin, J. Molecular cloning of a potential proteinase activated receptor. Proc. Natl. Acad. Sci. U S A. 1994, 91, 9208-9212.
26. Nystedt, S.; Emilsson, K.; Larsson, A. K.; Strömbeck, B.; Sundelin, J. Protease-activated receptor-2 (PAR-2): A potential new target in arthritis. Eur. J. Biochem. 1995, 232, 84-89.
27. Bohm, S. K.; Kong, W.; Bromme, D.; Smeekens, S. P.; Anderson, D. C.; Connolly, A.; Kahn, M.; Nelken, N. A.; Coughlin, S. R.; Payan, D. G.; Bunnett, N. W. Molecular cloning, expression and potential functions of the human proteinase-activated receptor-2. Biochem. J. 1996, 314, 1009-1016.
28. Kinlough-Rathbone, R. L.; Perry, D.W.; Guccione, M. A.; Rand, M. L.; Packham, M. A. Degranulation of human platelets by the thrombin receptor peptide SFLLRN: comparison with degranulation by thrombin. Thromb. Haemost. 1993, 70, 1019-1023.
29. Connolly, A. J.; Ishihara, H.; Kahn, M. L.; Farese, R.V. Jr.; Coughlin, S.R. Role of the thrombin receptor in development and evidence for a second receptor. Nature 1996, 381, 516-519.
30. Ishihara, H.; Connolly, A. J.; Zeng, D.; Kahn, M. L.; Zheng, Y. W.; Timmons, C.; Tram, T.; Coughlin, S. R. Protease-activated receptor 3 is a second thrombin receptor in humans. Nature 1997, 386, 502-506.
31. Kahn, M.L.; Zheng, Y. W.; Huang, W.; Bigornia, V.; Zeng, D.; Moff, S.; Farese, R.V. Jr.; Tam, C.; Coughlin, S. R. A dual thrombin receptor system for platelet activation. Nature 1998, 394, 690-694.
32. Ishihara, H.; Zeng, D.; Connolly, A. J.; Tam, C.; Coughlin, S. R. Antibodies to protease-activated receptor 3 inhibit activation of mouse platelets by thrombin. Blood 1998, 91, 4152-4157.
33. Xu, W. F.; Andersen, H.; Whitmore, T. E.; Presnell, S. R.; Yee, D. P.; Ching, A.; Gilbert, T.; Davie, E. W.; Foster, D. C. Cloning and characterization of human protease-activated receptor 4. Proc. Natl. Acad. Sci. USA 1998, 95, 6642-6646.
34. Kahn, M. L.; Nakanishi-Matsui, M.; Shapiro, M. J.; Ishihara, H.; Coughlin, S. R. Protease-activated receptors 1 and 4 mediate activation of human platelets by thrombin. J. Clin. Invest. 1999, 103, 879-887.
35. Faruqi, T. R.; Weiss, E. J.; Shapiro, M. J.; Huang, W.; Coughlin, S. R. Structure-function analysis of protease-activated receptor 4 tethered ligand peptides. Determinants of specificity and utility in assays of receptor function. J. Biol. Chem. 2000, 275, 19728-19734.
36. Nakanishi-Matsui, M.; Zheng, Y. W.; Sulciner, D. J.; Weiss, E. J.; Ludeman, M. J.; Coughlin, S. R. PAR3 is a cofactor for PAR4 activation by thrombin. Nature 2000, 404, 609-613.
37. Derian, C. K.; Maryanoff, B. E.; Zhang, H. C.; Andrade-Gordon, P. Therapeutic potential of protease-activated receptor-1 antagonists. Expert. Opin. Investig. Drugs 2003, 12, 209-221.
38. Trejo, J. Regulation of thrombin receptor signaling. In Thrombin: Physiology and Disease, Maragoudakis, M. E.; Tsopanoglou, N. E., Eds. Springer: New York, 2009, pp. 47-61.
39. Vu, T. K.; Wheaton, V. I.; Hung, D. T.; Charo, I.; Coughlin, S.R. Domains specifying thrombin-receptor interaction. Nature 1991, 353, 674-677.
40. Kataoka, H.; Hamilton, J. R.; McKemy, D. D.; Camerer, E.; Zheng, Y. W.; Cheng, A.; Griffin, C.; Coughlin, S. R. Protease-activated receptors 1 and 4 mediate thrombin signaling in endothelial cells. Blood 2003, 102, 3224-3231.
41. O'Brien, P. J.; Prevost, N.; Molino, M.; Hollinger, M. K.; Woolkalis, M. J.; Woulfe, D. S.; Brass, L. F. Thrombin responses in human endothelial cells. Contributions from receptors other than PAR1 include the transactivation of PAR2 by thrombin-cleaved PAR1. J. Biol. Chem. 2000, 275, 13502-13509.
42. Gudmundsdóttir, I. J.; Megson, I. L.; Kell, J. S.; Ludlam, C. A.; Fox, K. A.; Webb, D. J.; Newby, D. E. Direct vascular effects of protease-activated receptor type 1 agonism in vivo in humans. Circulation 2006, 114, 1625-1632.
43. D'Andrea, M. R.; Derian, C. K.; Leturcq, D.; Baker, S. M.; Brunmark, A.; Ling, P.; Darrow, A. L.; Santulli, R. J.; Brass, L. F.; Andrade-Gordon, P. Characterization of protease-activated receptor-2 immunoreactivity in normal human tissues. J. Histochem. Cytochem. 1998, 46, 157-164.
44. Wang, H.; Ubl, J. J.; Reiser, G. Four subtypes of protease-activated receptors, co-expressed in rat astrocytes, evoke different physiological signaling. Glia 2002, 37, 53-63.
45. i mobilization in human astrocytoma cells. J. Cancer Res. Clin. Oncol. 2000, 126, 91-94.
46. Ishii, K.; Hein, L.; Kobilka, B.; Coughlin, S. R. Kinetics of thrombin receptor cleavage on intact cells. Relation to signaling. J. Biol. Chem. 1993, 268, 9780-9786.
47. De Candia, E.; Hall, S. W.; Rutella, S.; Landolfi, R.; Andrews, R. K.; De Cristofaro, R. Binding of thrombin to glycoprotein Ib accelerates the hydrolysis of Par-1 on intact platelets. J. Biol. Chem. 2001, 276, 4692-4698.
48. Camerer, E.; Huang, W.; Coughlin, S. R. Tissue factor- and factor X-dependent activation of protease-activated receptor 2 by factor VIIa. Proc. Natl. Acad. Sci. USA 2000, 97, 5255-5260.
49. Schaffner, F.; Ruf, W. Tissue factor and protease-activated receptor signaling in cancer. Semin. Thromb. Hemost. 2008, 34, 147-153.
50. Riewald, M.; Ruf, W. Mechanistic coupling of protease signaling and initiation of coagulation by tissue factor. Proc. Natl. Acad. Sci. USA 2001, 98, 7742-7747.
51. Riewald, M.; Kravchenko, V. V.; Petrovan, R. J.; O'Brien, P. J.; Brass, L. F.; Ulevitch, R. J.; Ruf, W. Gene induction by coagulation factor Xa is mediated by activation of protease-activated receptor 1. Blood 2001, 97, 3109-3116.
52. Borensztajn, K.; Peppelenbosch, M. P.; Spek, C. A. Factor Xa: at the crossroads between coagulation and signaling in physiology and disease. Trends Mol. Med. 2008, 14, 429-440.
53. Camerer, E.; Kataoka, H.; Kahn, M.; Lease, K.; Coughlin, S. R. Genetic evidence that protease-activated receptors mediate factor Xa signaling in endothelial cells. J. Biol. Chem. 2002, 277, 16081-16087.
54. Riewald, M. Thrombin and activated protein C: Integrated to refulate vascular physiology. In Thrombin: Physiology and Disease, Maragoudakis, M. E.; Tsopanoglou, N. E., Eds. Springer: New York, 2009, pp. 63-80.
55. Riewald, M.; Petrovan, R. J.; Donner, A.; Mueller, B. M.; Ruf, W. Activation of endothelial cell protease activated receptor 1 by the protein C pathway. Science 2002, 296, 1880-1882.
56. Cheng, T.; Liu, D.; Griffin, J. H.; Fernández, J. A.; Castellino, F.; Rosen, E. D.; Fukudome, K.; Zlokovic, B. V. Activated protein C blocks p53-mediated apoptosis in ischemic human brain endothelium and is neuroprotective. Nat. Med. 2003, 9, 338-342.
57. Ramachandran, R.; El-Daly, M.; Saifeddine, M.; Hollenberg. Thrombin: To PAR or not to PAR, and the regulation of inflammation. In Thrombin: Physiology and Disease, Maragoudakis, M. E.; Tsopanoglou, N. E., Eds. Springer: New York, 2009, pp. 19-46.
58. Mannaioni, G.; Orr, A. G.; Hamill, C. E.; Yuan, H.; Pedone, K. H.; McCoy, K. L.; Berlinguer Palmini, R.; Junge, C. E.; Lee, C. J.; Yepes, M.; Hepler, J. R.; Traynelis, S.F. Plasmin potentiates synaptic N-methyl-D-aspartate receptor function in hippocampal neurons through activation of protease-activated receptor-1. J. Biol. Chem. 2008, 283, 20600-20611.
59. Hollenberg, M. D.; Oikonomopoulou, K.; Hansen, K. K.; Saifeddine, M.; Ramachandran, R.; Diamandis, E. P. Kallikreins and proteinase-mediated signaling: proteinase-activated receptors (PARs) and the pathophysiology of inflammatory diseases and cancer. Biol. Chem. 2008, 89, 643-651.
60. Lourbakos, A.; Potempa, J.; Travis, J.; D'Andrea, M. R.; Andrade-Gordon, P.; Santulli, R.; Mackie, E. J.; Pike, R. N. Infect. Immun. 2001, 69, 5121-5130.
61. Lourbakos, A.; Yuan, Y. P.; Jenkins, A. L.; Travis, J.; Andrade-Gordon, P.; Santulli, R.; Potempa, J.; Pike, R. N. Activation of protease-activated receptors by gingipains from Porphyromonas gingivalis leads to platelet aggregation: a new trait in microbial pathogenicity. Blood 2001, 97, 3790-3797.
62. Ayala, Y. M.; Cantwell, A. M.; Rose, T.; Bush, L. A.; Arosio, D.; Di Cera, E. Molecular mapping of thrombin-receptor interactions. Proteins 2001, 45, 107-116.
63. Nieman, M. T.; Schmaier, A. H. Interaction of thrombin with PAR1 and PAR4 at the thrombin cleavage site. Biochemistry 2007, 46, 8603-8610.
64. Mathews, I. I.; Padmanabhan, K. P.; Ganesh, V.; Tulinsky, A.; Ishii, M.; Chen, J.; Turck, C. W.; Coughlin, S. R. Crystallographic structures of thrombin complexed with thrombin receptor peptides: existence of expected and novel binding modes. Biochemistry 1994, 33, 3266-3279.
65. Jacques, S. L.; LeMasurier, M.; Sheridan, P. J.; Seeley, S. K.; Kuliopulos, A. Substrate-assisted catalysis of the PAR1 thrombin receptor. Enhancement of macromolecular association and cleavage. J. Biol. Chem. 2000, 275, 40671-40678.
66. Myles, T.; Le Bonniec, B. F.; Stone, S. R. The dual role of thrombin's anion-binding exosite-I in the recognition and cleavage of the protease-activated receptor 1. Eur. J. Biochem. 2001, 268, 70-77.
67. Gandhi, P. S.; Chen, Z.; Mathews, F. S.; Di Cera, E. Structural identification of the pathway of long-range communication in an allosteric enzyme. Proc. Natl. Acad. Sci. USA 2008, 105, 1832-1837.
68. Covic, L.; Gresser, A. L.; Kuliopulos, A. Biphasic kinetics of activation and signaling for PAR1 and PAR4 thrombin receptors in platelets. Biochemistry 2000, 39, 5458-54567.
69. Bahou, W. F.; Kutok, J. L.; Potter, C. L.; Coller, B. S. Identification of a novel thrombin receptor sequence required for activationdependent responses. Blood 1994, 84, 4195-4202.
70. Nanevicz, T.; Ishii, M.; Chen, J.; Turck, C. W.; Cohen, F. E.; Coughlin, S. R. Mechanisms of thrombin receptor agonist specificity. Chimeric receptors and complementary mutations identify an agonist recognition site. J. Biol. Chem. 1995, 270, 21619-21625.
71. Vouret-Craviari, V.; Van Obberghen-Schilling, E.; Rasmussen, U. B.; Pavirani, A.; Lecocq, J. P.; Pouysségur, J. Synthetic alphathrombin receptor peptides activate G protein-coupled signaling pathways but are unable to induce mitogenesis. Mol. Biol. Cell 1992, 3, 95-102.
72. Vouret-Craviari, V.; Van Obberghen-Schilling, E.; Scimeca, J. C.; Van Obberghen, E.; Pouysségur J. Differential activation of p44mapk (ERK1) by alpha-thrombin and thrombin-receptor peptide agonist. Biochem. J. 1993, 289, 209-214.
73. Feng, D. M.; Veber, D. F.; Connolly, T. M.; Condra, C.; Tang M. J.; Nutt, R. F. Development of a potent thrombin receptor ligand. J Med Chem. 1995, 38, 4125-4130.
74. Ceruso, M. A.; McComsey, D. F.; Leo, G. C.; Andrade-Gordon, P.; Addo, M. F.; Scarborough, R. M.; Oksenberg, D.; Maryanoff, B. E. Thrombin receptor-activating peptides (TRAPs): investigation of bioactive conformations via structure-activity, spectroscopic, and computational studies. Bioorg. Med. Chem. 1999, 7, 2353-2371.
75. Scarborough, R. M.; Naughton, M. A.; Teng, W.; Hung, D. T.; Rose, J.; Vu, T. K.; Wheaton, V. I.; Turck, C. W.; Coughlin, S. R. Tethered ligand agonist peptides. Structural requirements for thrombin receptor activation reveal mechanism of proteolytic unmasking of agonist function. J. Biol. Chem. 1992, 267, 13146-13149.
76. Chao, B. H.; Kalkunte, S.; Maraganore, J. M.; Stone, S. R. Essential roups in synthetic agonist peptides for activation of the platelet hrombin receptor. Biochemistry 1992, 31, 6175-6178.
77. Vassallo, R. R. Jr.; Kieber-Emmons, T.; Cichowski, K.; Brass, L.F. Structure-function relationships in the activation of platelet thrombin receptors by receptor-derived peptides. J. Biol. Chem. 1992, 267, 6081-6085.
78. Sabo, T.; Gurwitz, D.; Motola, L.; Brodt, P.; Barak, R.; Elhanaty, E. Structure-activity studies of the thrombin receptor activating peptide. Biochem. Biophys. Res. Commun. 1992, 188, 604-610.
79. Natarajan, S.; Riexinger, D.; Peluso, M.; Seiler, S. M. 'Tethered ligand' derived pentapeptide agonists of thrombin receptor: a study of side chain requirements for human platelet activation and GTPase stimulation. Int. J. Pept. Protein Res. 1995, 45, 145-151.
80. Barry, G. D.; Le, G. T.; Fairlie, D. P. Agonists and antagonists of protease activated receptors (PARs). Curr. Med. Chem. 2006, 13, 243-265.
81. Chen, C.; Maryanoff, B. E.; Andrade-Gordon, P. Thrombin receptor modulators: Medicinal chemistry, biological evaluation, and clinical application. In Thrombin: Physiology and Disease, Maragoudakis, M. E.; Tsopanoglou, N. E., Eds. Springer: New York, 2009, pp. 205-236.
82. Mao, Y.; Jin, J.; Kunapuli, S.P. Characterization of a new peptide agonist of the protease-activated receptor-1. Biochem. Pharmacol. 2008, 75, 438-447.
83. Maryanoff, B. E.; Zhang, H. C.; Andrade-Gordon, P.; Derian, C. K. Discovery of potent peptide-mimetic antagonists for the human thrombin receptor, protease-activated receptor-1 (PAR-1). Curr. Med. Chem. Cardiovas. Hematol. Agents 2003, 1, 13-36.
84. Chackalamannil, S. Thrombin receptor (protease activated receptor-1) antagonists as potent antithrombotic agents with strong antiplatelet effects. J. Med. Chem. 2006, 49, 5389-5403.
85. Bernatowicz, M. S.; Klimas, C. E.; Hartl, K. S.; Peluso, M.; Allegretto, N. J.; Seiler, S. M. Development of potent thrombin receptor antagonist peptides. J. Med. Chem. 1996, 39, 4879-4887.
86. Quinton, T. M.; Kim, S.; Derian, C. K.; Jin, J.; Kunapuli, S. P. Plasmin-mediated activation of platelets occurs by cleavage of protease-activated receptor 4. J. Biol. Chem. 2004, 279, 18434-18439.
87. Zhang, H. C.; Derian, C. K.; Andrade-Gordon, P.; Hoekstra, W. F.; Cheung, W. M.; Damiano, B. P.; Oksenberg, D.; Reynolds, E. E.; Pandey, A.; Scarborough, R. M.; Maryanoff, B. E. Discovery and optimization of a novel series of thrombin receptor (par-1) antagonists: potent, selective peptide mimetics based on indole and indazole templates. J. Med. Chem. 2001, 44, 1021-1024.
88. Derian, C. K.; Maryanoff, B. E.; Andrade-Gordon, P.; Zhang, H. C. Design and evaluation of potent peptide-mimetic PAR-1 Antagonists. Drug Dev. Res. 2003, 59, 355-366.
89. Valdivielso, A.M.; García-López, M. T.; Herranz, R. Improved synthesis of the PAR-1 thrombine receptor antagonist RWJ-58259. ARKIVOC 2008, XVII, 287-94.
90. Damiano, B. P.; Derian, C. K.; Maryanoff, B. E.; Zhang, H. C.; Gordon, P. A. RWJ-58259: a selective antagonist of protease activated receptor-1. Cardiovasc. Drug Rev. 2003, 21, 313-326.
91. Derian, C. K.; Damiano, B. P.; Addo, M. F.; Darrow, A. L.; D'Andrea, M. R.; Nedelman, M.; Zhang, H. C.; Maryanoff, B. E.; Andrade-Gordon, P. Blockade of the thrombin receptor proteaseactivated receptor-1 with a small-molecule antagonist prevents thrombus formation and vascular occlusion in nonhuman primates. J. Pharmacol. Exp. Ther. 2003, 304, 855-861.
92. Severino, B.; Fiorino; F.; Perissutti, E.; Frecentese, F.; Cirino, G.; Roviezzo, F.; Santagada, V.; Caliendo G. Synthesis and pharmacological evaluation of peptide-mimetic protease-activated receptor-1 antagonists containing novel heterocyclic scaffolds. Bioorg. Med. Chem. 2008, 16, 6009-6020.
93. Kato, Y.; Kita, Y.; Nishio, M.; Hirasawa, Y.; Ito, K.; Yamanaka, T.; Motoyama, Y.; Seki, J. In vitro antiplatelet profile of FR171113, a novel non-peptide thrombin receptor antagonist. Eur. J. Pharmacol. 1999, 384, 197-202.
94. Kato, Y.; Kita, Y.; Hirasawa-Taniyama, Y.; Nishio, M.; Mihara, K.; Ito, K.; Yamanaka, T.; Seki, J.; Miyata, S.; Mutoh, S. Inhibition of arterial thrombosis by a protease-activated receptor 1 antagonist, FR171113, in the guinea pig. Eur. J. Pharmacol. 2003, 473, 163-169.
95. Barrow, J. C.; Nantermet, P. G.; Selnick, H. G.; Glass, K. L.; Ngo, P. L.; Young, M. B.; Pellicore, J. M.; J. Breslin, M. J.; Hutchinson, J. H.; Freidinger, R. M.; Condra, C.; Karczewski, J.; Bednar, R. A.; Gaul, S. L.; Stern, A.; Gould, R.; M. Connolly, T. M. Discovery and initial structure-activity relationships of trisubstituted ureas as thrombin receptor (PAR-1) antagonists. Bioorg. Med. Chem. Lett. 2001, 11, 2691-2696.
96. Nantermet, P. G.; Barrow, J. C.; Lundell, G. F.; Pellicore, J. M.; Rittle, K. E.; Young, M. B.; Freidinger, R. M.; Connolly, T. M.; Condra, C.; Karczewski, J.; Bednar, R. A.; Gaul, S. L.; Gould, R. J.; Prendergast, K.; Selnick, H. G. Discovery of a nonpeptidic small molecule antagonist of the human platelet thrombin receptor (PAR-1). Bioorg. Med. Chem. Lett. 2002, 12, 319-323.
97. Ahn, H.S.; Arik, L.; Boykow, G.; Burnett, D.A.; Caplen, M. A.; Czarniecki, M.; Domalski, M. S.; Foster, C.; Manna, M.; Stamford, A. W.; Wu, Y. Structure-activity relationships of pyrroloquinazolines as thrombin receptor antagonists. Bioorg. Med. Chem. Lett. 1999, 9, 2073-2078.
98. Ahn, H.S.; Foster, C.; Boykow, G.; Stamford, A. W.; Manna, M.; Graziano, M. Inhibition of cellular action of thrombin by N3-cyclopropyl-7-[[4-(1- methylethyl)phenyl] methyl]-7H-pyrrolo[3, 2-f]quinazoline-1,3-diamine (SCH 79797), a nonpeptide thrombin receptor antagonist. Biochem. Pharmacol. 2000, 60, 1425-1434.
99. Ma, L.; Perini, R.; McKnight, W.; Dicay, M.; Klein, A.; Hollenberg, M. D.; Wallace, J. L. Proteinase-activated receptors 1 and 4 counter-regulate endostatin and VEGF release from human platelets. Proc. Natl. Acad. Sci. USA 2005, 102, 216-220
100. Kaufmann, R.; Rahn, S.; Pollrich, K.; Hertel, J.; Dittmar, Y.; Hommann, M.; Henklein, P.; Biskup, C.; Westermann, M.; Hollenberg, M. D.; Settmacher, U. Thrombin-mediated hepatocellular carcinoma cell migration: cooperative action via proteinaseactivated receptors 1 and 4. J. Cell Physiol. 2007, 211, 699-707.
101. Strande, J. L.; Hsu, A.; Su, J.; Fu, X.; Gross, G. J.; Baker, J. E. SCH 79797, a selective PAR1 antagonist, limits myocardial ischemia/reperfusion injury in rat hearts. Basic Res Cardiol. 2007, 102, 350-358.
102. Di Serio, C.; Pellerito, S.; Duarte, M.; Massi, D.; Naldini, A.; Cirino. G.; Prudovsky, I.; Santucci, M.; Geppetti, P.; Marchionni, N.; Masotti, G.; Tarantini, F. Protease-activated receptor 1-selective antagonist SCH79797 inhibits cell proliferation and induces apoptosis by a protease-activated receptor 1-independent mechanism. Basic Clin. Pharmacol. Toxicol. 2007, 101, 63-69.
103. Chackalamannil, S.; Doller, D.; Eagen, K.; Michael Czarniecki, M.; Ahn, H. S.; Foster, C. J.; Boykow, G. Potent, low molecular weight thrombin receptor antagonists. Bioorg. Med. Chem. Lett. 2001, 11, 2851-2853.
104. Suzuki, S.; Kotake, M.; Miyamoto, M.; Kawahara, T.; Kajiwara, A.; Hishinuma, I.; Okano, K.; Miyazawa, S.; Clark, R.; Ozaki, F.; Sato, N.; Shinoda, M.; Kamada, A.; Tsukada, I.; Matsuura, F.; Naoe, Y.; Terauchi, T.; Oohashi, Y.; Ito, O.; Tanaka, H.; Musya, T.; Kogushi, M.; Kawada, T.; Matsuoka, T.; Kobayashi, H.; Chiba, K.; Kimura, A.; Ono, N. 2-Iminoimidazole derivative. PCT Int. Appl. WO 2002/088092.
105. Suzuki, S.; Kotake, M.; Miyamoto, M.; Kawahara, T.; Kajiwara, A.; Hishinuma, I.; Okano, K.; Miyazawa, S.; Clark, R.; Ozaki, F.; Sato, N.; Shinoda, M.; Kamada, A.; Tsukada, I.; Matsuura, F.; Naoe, Y.; Terauchi, T.; Oohashi, Y.; Ito, O.; Tanaka, H.; Musya, T.; Kogushi, M.; Kawada, T.; Matsuoka, T.; Kobayashi, H.; Chiba, K.; Kimura, A.; Ono, N. - 2-Iminopyrrolidine derivatives. PCT Int. Appl. WO 2002/085855.
106. Suzuki, S.; Kotake, M.; Miyamoto, M.; Kawahara, T.; Kajiwara, A.; Hishinuma, I.; Okano, K.; Miyazawa, S.; Clark, R.; Ozaki, F.; Sato, N.; Shinoda, M.; Kamada, A.; Tsukada, I.; Matsuura, F.; Naoe, Y.; Terauchi, T.; Oohashi, Y.; Ito, O.; Tanaka, H.; Musya, T.; Kogushi, M.; Kawada, T.; Matsuoka, T.; Kobayashi, H.; Chiba, K.; Kimura, A.; Ono, N. Cyclic amidine derivative. PCT Int. Appl. WO 2002/085850.
107. http://clinicaltrials.gov/ct2/show/NCT00540670.
108. Linkins, L.A.; Eikelboom, J.W.; Turpie, A.G. Emerging oral antiplatelet receptor inhibitors. In Clinical Guide to the Use of Antithrombotic Drugs in Coronary Artery Disease, Angiolillo, D.;Kastrati, K.; Simon, D., Eds. Informa Healthcare:London, 2008, pp. 91-97.
109. Chackalamannil, S.; Xia, Y.; Greenlee, W. J.; Clasby, M.; Doller, D.; Tsai, H.; Asberom, T.; Czarniecki, M.; Ahn, H-S.; Boykow, G.; Foster, C.; Agans-Fantuzzi, J.; Bryant, M.; Lau, J.; Chintala, M. Discovery of potent orally active thrombin receptor (protease activated receptor 1) antagonists as novel antithrombotic agents. J. Med. Chem. 2005, 48, 5884-5887.
110. http://clinicaltrials.gov/ct2/show/NCT00527943
111. http://clinicaltrials.gov/ct2/show/NCT00526474 and NCT00617123.
112. Boire, A.; Covic, L.; Agarwal, A.; Jacques, S.; Sherifi, S.; Kuliopulos, A. PAR1 is a matrix metalloprotease-1 receptor that promotes invasion and tumorigenesis of breast cancer cells. Cell 2005, 120, 303-313.
113. Flemming, A. Bacterial sepsis: Pepducins to the rescue. Nature Rev. Drug Discov. 2005, 4, 538-539
114. Covic, L.; Gresser, A.L.; Talavera, J.; Swift, S.; Kuliopulos, A. Activation and inhibition of G protein-coupled receptors by cellpenetrating membrane-tethered peptides. Proc. Natl. Acad. Sci. USA 2002, 99, 643-648.
115. Covic, L.; Misra, M.; Badar, J.; Singh, C.; Kuliopulos, A. Pepducin-based intervention of thrombin-receptor signaling and systemic platelet activation. Nat. Med. 2002, 8, 1161-1165.
116. Kostenis, E.; Conklin, B. R.; Wess, J. Molecular basis of receptor/G protein coupling selectivity studied by coexpression of wild type and mutant m2 muscarinic receptors with mutant G alpha(q) subunits. Biochemistry 1997, 36, 1487-1495.
117. Nguyen, Q. D.; Faivre, S.; Bruyneel, E.; Rivat, C.; Seto, M.; Endo, T.; Mareel, M.; Emami, S.; Gespach, C. RhoA- and RhoDdependent regulatory switch of Galpha subunit signaling by PAR-1 receptors in cellular invasion. FASEB J. 2002, 16, 565-576.
118. McLaughlin, J. N.; Shen, L.; Holinstat, M.; Brooks, J. D.; Dibenedetto, E.; Hamm, H. E. Functional selectivity of G protein signaling by agonist peptides and thrombin for the proteaseactivated receptor-1. J. Biol. Chem. 2005, 280, 25048-25059.
119. Gavard, J.; Gutkind, J. S. Protein kinase C-related kinase and ROCK are required for thrombin-induced endothelial cell permeability downstream from Galpha12/13 and Galpha11/q. J. Biol. Chem. 2008, 283, 29888-29896.
120. De Vries, L.; Palmier, C.; Finana, F.; Le Grand, B.; Perez, M.; Cussac, D. Pharmacological characterization of protease activated receptor-1 by a serum responsive element-dependent reporter gene assay: major role of calmodulin. Biochem. Pharmacol. 2006, 71, 1449-1458.
121. Klages, B.; Brandt, U.; Simon, M. I.; Schultz, G.; Offermanns, S. Activation of G12/G13 results in shape change and Rho/Rhokinase-mediated myosin light chain phosphorylation in mouse platelets. J. Cell Biol. 1999, 144, 745-754.
122. Huang, J. S.; Dong, L.; Kozasa, T.; Le Breton, G. C. Signaling through G(alpha)13 switch region I is essential for proteaseactivated receptor 1-mediated human platelet shape change, aggregation, and secretion. J. Biol. Chem. 2007, 282, 10210-10222.
123. Vouret-Craviari, V.; Boquet, P.; Pouysségur, J.; Van Obberghen-Schilling, E. Regulation of the actin cytoskeleton by thrombin in human endothelial cells: role of Rho proteins in endothelial barrier function. Mol. Biol. Cell. 1998, 9, 2639-2653.
124. Offermanns, S.; Mancino, V.; Revel, J. P.; Simon, M. I. Vascular system defects and impaired cell chemokinesis as a result of Galpha13 deficiency. Science 1997, 275, 533-536.
125. Nguyen, Q. D.; De Wever, O.; Bruyneel, E.; Hendrix, A.; Xie, W. Z.; Lombet, A.; Leibl, M.; Mareel, M.; Gieseler, F.; Bracke, M.; Gespach, C. Commutators of PAR-1 signaling in cancer cell invasion reveal an essential role of the Rho-Rho kinase axis and tumor microenvironment. Oncogene 2005, 24, 8240-8251.
126. Hatziapostolou, M.; Polytarchou, C.; Panutsopulos, D.; Covic, L.; Tsichlis, P. N. Proteinase-activated receptor-1-triggered activation of tumor progression locus-2 promotes actin cytoskeleton reorganization and cell migration. Cancer Res. 2008, 68, 1851-1861.
127. Furuhashi, I.; Abe, K.; Sato, T.; Inoue, H. Thrombin-stimulated proliferation of cultured human synovial fibroblasts through proteolytic activation of proteinase-activated receptor-1. J. Pharmacol. Sci. 2008, 108, 104-111.
128. Palma-Nicolas, J. P.; López, E.; López-Colomé, A. M. PKC isoenzymes differentially modulate the effect of thrombin on MAPKdependent RPE proliferation. Biosci. Rep. 2008, 28, 307-317.
129. Chiu, Y. C.; Fong, Y. C.; Lai, C. H.; Hung, C. H.; Hsu, H. C.; Lee, T. S.; Yang, R. S.; Fu, W. M.; Tang, C. H. Thrombin-induced IL-6 production in human synovial fibroblasts is mediated by PAR1, phospholipase C, protein kinase C alpha, c-Src, NF-kappa B and p300 pathway. Mol. Immunol. 2008, 45, 1587-1599.
130. Huang, Y. L.; Shi, G. Y.; Lee, H.; Jiang, M. J.; Huang, B. M.; Wu, H. L.; Yang, H. Y. Thrombin induces nestin expression via the transactivation of EGFR signalings in rat vascular smooth muscle cells. Cell Signal 2009, 21, 954-968.
131. Arora, P.; Cuevas, B. D.; Russo, A.; Johnson, G. L.; Trejo, J. Persistent transactivation of EGFR and ErbB2/HER2 by proteaseactivated receptor-1 promotes breast carcinoma cell invasion. Oncogene 2008, 27, 4434-4445.
132. Faivre, S.; Régnauld, K.; Bruyneel, E.; Nguyen, Q. D.; Mareel, M.; Emami, S.; Gespach, C. Persistent transactivation of EGFR and ErbB2/HER2 by protease-activated receptor-1 promotes breast carcinoma cell invasion. Mol. Pharmacol. 2001, 60, 363-372.
133. Wang, H.; Ubl, J. J.; Stricker, R.; Reiser, G. Thrombin (PAR-1)-induced proliferation in astrocytes via MAPK involves multiple signaling pathways. Am. J. Physiol. Cell Physiol. 2002, 283, C1351-1364.
134. Wolfe, B. L.; Marchese, A.; Trejo, J. Ubiquitination differentially regulates clathrin-dependent internalization of protease-activated receptor-1. J. Cell Biol. 2007, 177, 905-916.
135. Ishii, K.; Chen, J.; Ishii, M.; Kock, W. J.; Freedman, N. J.; Lefkowitz, R. J.; Coughlin, S. R. Inhibition of thrombin receptor signaling by a G-protein coupled receptor kinase. Functional specificity among G-protein coupled receptor kinases. J. Biol. Chem. 1994, 269, 1125-1130.
136. Paing, M. M.; Stutts, A. B.; Kohout, T. A.; Lefkowitz, R. J.; Trejo, J. beta -Arrestins regulate protease-activated receptor-1 desensitization but not internalization or Down-regulation. J. Biol. Chem. 2002, 277, 1292-1300.
137. Sambrano G.R.; Coughlin S. R. The carboxyl tail of proteaseactivated receptor-1 is required for chemotaxis. Correlation of signal termination and directional migration. J. Biol. Chem. 1999, 274, 20178-84.
138. Trejo, J.; Hammes S. R.; Coughlin S. R. Termination of signaling by protease-activated receptor-1 is linked to lysosomal sorting. Proc. Natl. Acad. Sci. USA 1998, 95, 13698-13702.
139. Lyman, G. H.; Khorana, A. A.; Kuderer, N. M.; Lee, A. Y. Cancer and thrombosis: back to the future renewed interest in an old problem. Cancer Invest. 2009, 27, 472-473.
140. Trousseau, A. In Lectures on Clinical Medicine. New Sydenham Society: London, 1865, pp. 281-295.
141. Shen, V. S.; Pollak, E. W. Fatal pulmonary embolism in cancer patients: is heparin prophylaxis justified? South. Med. J. 1980, 73, 841-843.
142. Svendsen, E.; Karwinski, B. Prevalence of pulmonary embolism at necropsy in patients with cancer. J. Clin. Pathol. 1989, 42, 805-899.
143. Rickles, F. R.; Edwards, R. L. Activation of blood coagulation in cancer: Trousseau's syndrome revisited. Blood 1983, 62, 14-31.
144. Petralia, G. A.; Kakkar, A. K. Anti-thrombotic therapy in cancer patients. In Thrombin: Physiology and Disease, Maragoudakis, M. E.; Tsopanoglou, N. E., Eds. Springer: New York, 2009, pp. 189-203.
145. Prandoni, P.; Lensing, A. W.; Büller, H. R.; Cogo, A.; Prins, M. H.; Cattelan, A. M.; Cuppini, S.; Noventa, F.; ten Cate, J. W. Deepvein thrombosis and the incidence of subsequent symptomatic cancer. N. Engl. J. Med. 1992, 327, 1128-1133.
146. Sørensen, H. T.; Mellemkjaer, L.; Olsen, J. H.; Baron, J. A. Prognosis of cancers associated with venous thromboembolism. N. Engl. J. Med. 2000, 343, 1846-1850.
147. Kakkar, A. K. An expanding role for antithrombotic therapy in cancer patients. Cancer Treat. Rev. 2003, 29, 23-26.
148. Zacharski, L. R.; Henderson, W. G.; Rickles, F. R.; Forman, W. B.; Cornell, C. J. Jr.; Forcier, R. J.; Edwards, R. L.; Headley, E.; Kim, S. H.; O'Donnell, J. F.; O'Dell, R.; Tornyos, K.; Kwaan, H. C. Effect of warfarin anticoagulation on survival in carcinoma of the lung, colon, head and neck, and prostate. Final report of VA Cooperative Study #75. Cancer 1984, 53, 2046-2052.
149. Lebeau, B.; Chastang, C.; Brechot, J. M.; Capron, F.; Dautzenberg, B.; Delaisements, C.; Mornet, M.; Brun, J.; Hurdebourcq, J. P.; Lemarie, E. Subcutaneous heparin treatment increases survival in small cell lung cancer. "Petites Cellules" Group. Cancer 1994, 74, 38-45.
150. Altinbas, M.; Coskun, H. S.; Er, O.; Ozkan, M.; Eser, B.; Unal, A.; Cetin, M.; Soyuer, S. A randomized clinical trial of combination chemotherapy with and without low-molecular-weight heparin in small cell lung cancer. J. Thromb. Haemost. 2004, 2, 1266-1271.
151. Kakkar, A. K.; Levine, M. N.; Kadziola, Z.; Lemoine, N. R.; Low, V.; Patel, H. K.; Rustin, G.; Thomas, M.; Quigley, M.; Williamson, R. C. Low molecular weight heparin, therapy with dalteparin, and survival in advanced cancer: the fragmin advanced malignancy outcome study (FAMOUS). J. Clin. Oncol. 2004, 22, 1944-1948.
152. Klerk, C. P.; Smorenburg, S. M.; Otten, H. M.; Lensing, A. W.; Prins, M. H.; Piovella, F.; Prandoni, P.; Bos, M. M.; Richel, D. J.; van Tienhoven, G.; Büller, H. R. The effect of low molecular weight heparin on survival in patients with advanced malignancy. J. Clin. Oncol. 2005, 23, 2130-2135.
153. Lee, A. Y.; Rickles, F. R.; Julian, J. A.; Gent, M.; Baker, R. I.; Bowden, C.; Kakkar, A. K.; Prins, M.; Levine, M. N. Randomized comparison of low molecular weight heparin and coumarin derivatives on the survival of patients with cancer and venous thromboembolism. J. Clin. Oncol. 2005, 23, 2123-2129.
154. Leshchenko, IuM.; Miasoiedov, D. V.; Olicombining brevenichenko, H. P.; Koshel', K. V.; Iatsenko, S. M. The effect of low-molecular-weight heparin on the late follow-up results of the combined and complex treatment of patients with rectal cancer. Klin. Khir. 2007, 21-24.
155. Bobek, V.; Boubelik, M.; Fiserovà, A.; L'uptovcovà, M.; Vannucci, L.; Kacprzak, G.; Kolodzej, J.; Majewski, A. M.; Hoffman, R. M. Anticoagulant drugs increase natural killer cell activity in lung cancer. Lung Cancer 2005, 47, 215-223.
156. Kakkar, A. K.; DeRuvo, N.; Chinswangwatanakul, V.; Tebbutt, S.; Williamson, R. C. Extrinsic-pathway activation in cancer with high factor VIIa and tissue factor. Lancet 1995, 346, 1004-1005.
157. Zhang, Y.; Deng, Y.; Luther, T.; Müller, M.; Ziegler, R.; Waldherr, R.; Stern, D. M.; Nawroth, P. P. Tissue factor controls the balance of angiogenic and antiangiogenic properties of tumor cells in mice. J. Clin. Invest. 1994, 94, 1320-1327.
158. Zacharski, L. R.; Memol, V. A.; Morain, W. D.; Schlaeppi, J. M.; Rousseau, S. M. Cellular localization of enzymatically active thrombin in intact human tissues by hirudin binding. Thromb. Haemost. 1995, 73, 793-797.
159. Geaquinto, D. L.; Fernandes, R. S.; Lima, L. G.; Barja-Fidalgo, C.; Monteiro, R. Q. Procoagulant properties of human MV3 melanoma cells. Braz. J. Med. Biol. Res. 2008, 41, 99-105.
160. Nierodzik, M. L.; Plotkin, A.; Kajumo, F.; Karpatkin, S. Thrombin stimulates tumor-platelet adhesion in vitro and metastasis in vivo. J. Clin. Invest. 1991, 87, 229-236.
161. Hu, L.; Lee, M.; Campbell, W.; Perez-Soler, R.; Karpatkin, S. Role of endogenous thrombin in tumor implantation, seeding, and spontaneous metastasis. Blood 2004, 104, 2746-51.
162. Salah, Z.; Grisaru-Granovsky, S.; Maoz, M.; Uziely, B.; Cohen, I.; Turn, H.; Peretz, T.; Bar-Shavit, R. The role of thrombin and its receptors in epithelial malignancies: Lessons from a transgenic mouse model and transcriptional regulation. In Thrombin: Physiology and Disease, Maragoudakis, M. E.; Tsopanoglou, N. E., Eds. Springer: New York, 2009, pp. 173-188.
163. Tellez, C.; Bar-Eli, M. Role and regulation of the thrombin receptor (PAR-1) in human melanoma. Oncogene 2003, 22, 3130-3137.
164. Granovsky-Grisaru, S.; Zaidoun, S.; Grisaru, D.; Yekel, Y.; Prus, D.; Beller, U.; Bar-Shavit, R. The pattern of Protease Activated Receptor 1 (PAR1) expression in endometrial carcinoma. Gynecol. Oncol. 2006, 103, 802-806.
165. Even-Ram, S.; Uziely, B.; Cohen, P.; Grisaru-Granovsky, S.; Maoz, M.; Ginzburg, Y.; Reich, R.; Vlodavsky, I.; Bar-Shavit, R. Thrombin receptor overexpression in malignant and physiological invasion processes. Nat. Med. 1998, 4, 909-914.
166. Cooper, C. R.; Chay, C. H.; Gendernalik, J. D.; Lee, H. L.; Bhatia, J.; Taichman, R. S.; McCauley, L. K.; Keller, E. T.; Pienta, K. J. Stromal factors involved in prostate carcinoma metastasis to bone. Cancer 2003, 97, 739-747.
167. Yuan, T. C.; Lin, M. F. Protease-activated receptor 1: a role in prostate cancer metastasis. Clin. Prostate Cancer 2004, 3, 189-191.
168. Black, P. C.; Mize, G. J.; Karlin, P.; Greenberg, D. L.; Hawley, S. J.; True, L. D.; Vessella, R. L.; Takayama, T. K. Overexpression of protease-activated receptors-1,-2, and-4 (PAR-1, -2, and -4) in prostate cancer. Prostate 2007, 67, 743-756.
169. Zhang, X.; Wang, W.; True, L. D.; Vessella, R. L.; Takayama, T. K. Protease-activated receptor-1 is upregulated in reactive stroma of primary prostate cancer and bone metastasis. Prostate 2009, 69, 727-736.
170. Rudroff, C.; Seibold, S.; Kaufmann, R.; Zetina, C. C.; Reise, K.; Schäfer, U.; Schneider, A.; Brockmann, M.; Scheele, J.; Neugebauer, E. A. Expression of the thrombin receptor PAR-1 correlates with tumour cell differentiation of pancreatic adenocarcinoma in vitro. Clin. Exp. Metastasis 2002, 19, 181-189.
171. Grisaru-Granovsky, S.; Salah, Z.; Maoz, M.; Pruss, D.; Beller, U.; Bar-Shavit, R. Differential expression of protease activated receptor 1 (Par1) and pY397FAK in benign and malignant human ovarian tissue samples. Int. J. Cancer 2005, 113, 372-378.
172. Darmoul, D.; Gratio, V.; Devaud, H.; Lehy, T.; Laburthe, M. Aberrant expression and activation of the thrombin receptor proteaseactivated receptor-1 induces cell proliferation and motility in human colon cancer cells. Am. J. Pathol. 2003, 162, 1503-1513.
173. Zhang, X.; Hunt, J. L.; Landsittel, D. P.; Muller, S.; Adler-Storthz, K.; Ferris, R. L.; Shin, D. M.; Chen, Z. G. Correlation of proteaseactivated receptor-1 with differentiation markers in squamous cell carcinoma of the head and neck and its implication in lymph node metastasis. Clin. Cancer Res. 2004, 10, 8451-8459.
174. Jin, E.; Fujiwara, M.; Pan, X.; Ghazizadeh, M.; Arai, S.; Ohaki, Y.; Kajiwara, K.; Takemura, T.; Kawanami, O. Protease-activated receptor (PAR)-1 and PAR-2 participate in the cell growth of alveolar capillary endothelium in primary lung adenocarcinomas. Cancer 2003, 97, 703-713.
175. Ghio, P.; Cappia, S.; Selvaggi, G.; Novello, S.; Lausi, P.; Zecchina, G.; Papotti, M.; Borasio, P.; Scagliotti, G. V. Prognostic role of protease-activated receptors 1 and 4 in resected stage IB non-smallcell lung cancer. Clin. Lung Cancer 2006, 7, 395-400.
176. D'Andrea, M. R.; Derian, C. K.; Santulli, R. J.; Andrade-Gordon, P. Differential expression of protease-activated receptors-1 and -2 in stromal fibroblasts of normal, benign, and malignant human tissues. Am. J. Pathol. 2001, 158, 2031-2041.
177. Martin, C. B.; Mahon, G. M.; Klinger, M. B.; Kay, R. J.; Symons, M.; Der, C. J.; Whitehead, I. P. The thrombin receptor, PAR-1, causes transformation by activation of Rho-mediated signaling pathways. Oncogene 2001, 20, 1953-1963.
178. Salah, Z.; Maoz, M.; Pokroy, E.; Lotem, M.; Bar-Shavit, R.; Uziely, B. Protease-activated receptor-1 (hPar1), a survival factor eliciting tumor progression. Mol. Cancer Res. 2007, 5, 229-240.
179. Villares, G. J.; Zigler, M.; Wang, H.; Melnikova, V. O.; Wu, H.; Friedman, R.; Leslie, M. C.; Vivas-Mejia, P. E.; Lopez-Berestein, G.; Sood, A. K.; Bar-Eli, M. Targeting melanoma growth and metastasis with systemic delivery of liposome-incorporated proteaseactivated receptor-1 small interfering RNA. Cancer Res. 2008, 68, 9078-86.
180. Kepner, N.; Lipton, A. A mitogenic factor for transformed fibroblasts from human platelets. Cancer Res. 1981, 41, 430-2.
181. Möhle, R.; Green, D.; Moore, M. A.; Nachman, R, L.; Rafii, S. Constitutive production and thrombin-induced release of vascular endothelial growth factor by human megakaryocytes and platelets. Proc. Natl. Acad. Sci. USA 1997, 94, 663-668.
182. Li, J. J.; Huang, Y. Q.; Basch, R.; Karpatkin, S. Thrombin induces the release of angiopoietin-1 from platelets. Thromb. Haemost. 2001, 85, 204-206.
183. Boucharaba, A.; Serre, C. M.; Grès, S.; Saulnier-Blache, J. S.; Bordet, J. C.; Guglielmi, J.; Clézardin, P.; Peyruchaud, O. Plateletderived lysophosphatidic acid supports the progression of osteolytic bone metastases in breast cancer. J. Clin. Invest. 2004, 114, 1714-1725.
184. Nieswandt, B.; Hafner, M.; Echtenacher, B.; Männel, D. N. Lysis of tumor cells by natural killer cells in mice is impeded by platelets. Cancer Res. 1999, 59, 1295-1300.
185. Melnikova, V. O.; Villares, G. J.; Bar-Eli, M. Emerging Roles of PAR-1 and PAFR in Melanoma Metastasis. Cancer Microenviron. 2008, 1, 103-111.
186. Beaulieu, L. M.; Church, F. -C. Activated protein C promotes breast cancer cell migration through interactions with EPCR and PAR-1. Exp. Cell Res. 2007, 313, 677-687.
187. Page-McCaw, A.; Ewald, A. J.; Werb, Z. Matrix metalloproteinases and the regulation of tissue remodelling. Nat. Rev. Mol. Cell Biol. 2007, 8, 221-233.
188. Ala-aho, R.; Kähäri, V. M. Collagenases in cancer. Biochimie 2005, 87, 273-286.
189. Blackburn, J. S.; Brinckerhoff, C. E. Matrix metalloproteinase-1 and thrombin differentially activate gene expression in endothelial cells via PAR-1 and promote angiogenesis. Am. J. Pathol. 2008, 173, 1736-1746.
190. Sang, Q. X. Complex role of matrix metalloproteinases in angiogenesis. Cell Res. 1998, 8, 171-177.
191. Blackburn, J. S.; Rhodes, C. H.; Coon, C. I.; Brinckerhoff, C. E. RNA interference inhibition of matrix metalloproteinase-1 prevents melanoma metastasis by reducing tumor collagenase activity and angiogenesis. Cancer Res. 2007, 67, 10849-10858.
192. Nguyen, N.; Kuliopulos, A.; Graham, R. A.; Covic, L. Tumorderived Cyr61(CCN1) promotes stromal matrix metalloproteinase-1 production and protease-activated receptor 1-dependent migration of breast cancer cells. Cancer Res. 2006, 66, 2658-2665.
193. Agarwal, A.; Covic, L.; Sevigny, L. M.; Kaneider, N. C.; Lazarides, K.; Azabdaftari, G.; Sharifi, S.; Kuliopulos, A. Targeting a metalloprotease-PAR1 signaling system with cell-penetrating pepducins inhibits angiogenesis, ascites, and progression of ovarian cancer. Mol. Cancer Ther. 2008, 7, 2746-2757.
194. Trivedi, V.; Boire, A.; Tchernychev, B.; Kaneider, N. C.; Leger, A. J.; O'Callaghan, K.; Covic, L.; Kuliopulos, A. Platelet matrix metalloprotease-1 mediates thrombogenesis by activating PAR1 at a cryptic ligand site. Cell 2009, 137, 332-343.
195. Radjabi, A. R.; Sawada, K.; Jagadeeswaran, S.; Eichbichler, A.; Kenny, H. A.; Montag, A.; Bruno, K.; Lengyel, E. Thrombin induces tumor invasion through the induction and association of matrix metalloproteinase-9 and beta1-integrin on the cell surface. J. Biol. Chem. 2008, 283, 2822-2834.
196. Darmoul, D.; Gratio, V.; Devaud, H.; Peiretti, F.; Laburthe, M. Activation of proteinase-activated receptor 1 promotes human colon cancer cell proliferation through epidermal growth factor receptor transactivation. Mol. Cancer Res. 2004, 2, 514-22.
197. Liu, J.; Schuff-Werner, P.; Steiner, M. Thrombin/thrombin receptor (PAR-1)-mediated induction of IL-8 and VEGF expression in prostate cancer cells. Biochem. Biophys. Res. Commun. 2006, 343, 183-189.
198. Furukawa, Y.; Kawano, Y.; Fukuda, J.; Matsumoto, H.; Narahara, H. The production of vascular endothelial growth factor and metalloproteinase via protease-activated receptor in human endometrial stromal cells. Fertil. Steril. 2009, 91, 535-541.
199. Grisaru-Granovsky, S.; Maoz, M.; Barzilay, O.; Yin, Y. J.; Prus, D.; Bar-Shavit, R. Protease activated receptor-1, PAR1, promotes placenta trophoblast invasion and beta-catenin stabilization. J. Cell Physiol. 2009, 218, 512-521.
200. Salah, Z.; Maoz, M.; Cohen, I.; Pizov, G.; Pode, D.; Runge, M. S.; Bar-Shavit, R. Identification of a novel functional androgen response element within hPar1 promoter: implications to prostate cancer progression. FASEB J. 2005, 19, 62-72.
201. Salah, Z.; Maoz, M.; Pizov, G.; Bar-Shavit, R. Transcriptional regulation of human protease-activated receptor 1: a role for the early growth response-1 protein in prostate cancer. Cancer Res. 2007, 67, 9835-9843.
202. Salah, Z.; Haupt, S.; Maoz, M.; Baraz, L.; Rotter, V.; Peretz, T.; Haupt, Y.; Bar-Shavit, R. p53 Controls hPar1 function and expression. Oncogene 2008, 27, 6866-6874.
203. Caunt, M.; Huang, Y. Q.; Brooks, P. C.; Karpatkin, S. Thrombin induces neoangiogenesis in the chick chorioallantoic membrane. J. Thromb. Haemost. 2003, 1, 2097-102.
204. Tsopanoglou, N. E.; Maragoudakis, M. E. On the mechanism of thrombin-induced angiogenesis. Potentiation of vascular endothelial growth factor activity on endothelial cells by up-regulation of its receptors. J. Biol. Chem. 1999, 274, 23969-23976.
205. Huang, Y. Q.; Li, J. J.; Hu, L.; Lee, M.; Karpatkin, S. Thrombin induces increased expression and secretion of angiopoietin-2 from human umbilical vein endothelial cells. Blood 2002, 99, 1646-1650.
206. Möhle, R.; Green, D.; Moore, M. A.; Nachman, R. L.; Rafii, S. Constitutive production and thrombin-induced release of vascular endothelial growth factor by human megakaryocytes and platelets. Proc. Natl. Acad. Sci. U S A 1997, 94, 663-668.
207. Caunt, M.; Hu, L.; Tang, T.; Brooks, P. C.; Ibrahim, S.; Karpatkin, S. Growth-regulated oncogene is pivotal in thrombin-induced angiogenesis. Cancer Res. 2006, 66, 4125-4132.
208. Zania, P.; Gourni, D.; Aplin, A. C.; Nicosia, R. F.; Flordellis, C. S.; Maragoudakis, M. E.; Tsopanoglou. N. E. Parstatin, the cleaved peptide on proteinase-activated receptor 1 activation, is a potent inhibitor of angiogenesis. J. Pharmacol. Exp. Ther. 2009, 328, 378-389.
209. Strande, J. L.; Widlansky, M. E.; Tsopanoglou, N. E.; Su, J.; Wang, J.; Hsu, A.; Routhu, K. V.; Baker, J. E. Parstatin: a cryptic peptide involved in cardioprotection after ischaemia and reperfusion injury. Cardiovasc. Res. 2009, 83, 325-334.